LTD.;SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO.
发明人:
WU, LINGYUN,ZHANG, PENG,LI, JIAN,CHEN, SHUHUI
申请号：
CA3034796
公开号：
CA3034796A1
申请日:
2017.07.21
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.
